OS of over 20 months? Doesn’t this seem very unl
Post# of 153860
(Total Views: 429)
Posted On: 05/19/2024 11:09:53 AM
OS of over 20 months? Doesn’t this seem very unlikely? I’d expect maybe a few reaching 15 months. I hope that’s true but that would pretty bizarre leap in care especially since these were very progressive cases of cancer.
36 months would lead us to believe we basically cured cancer at this point? Maybe this is why the data is urgent?
I don’t want to get my hopes up, but once again ohm is this actually possible? Obviously nobody can really answer that without the data but this just seems too good to be true.
“Come 9/16/2022, we should be able to learn what the more refined PFS is for these 21 patients and what the more refined Overall Survivability is for these 21 patients. The study started 4/22/2019. By 7/19/21, the PFS was 8 months and the OS was 36 months. Since then, 13 months have passed. All in All, the patients were not very healthy. It was a combination of Compassionate Use, brain metastasis and patients had failed 2 other treatment protocols. Patients were treated differently, and may only have received up to 4 doses of leronlimab + carboplatin total while some other received much more, however, leronlimab may have been dosed even after PFS endpoint was reached and after the cancer had returned which may have extended OS. Hopefully, all of this is documented in the results of the trial. From the 7/19/21 PR above, we currently had a PFS of 8 months and an OS of 36 months. Since November 2021, the PFS was recalculated to be 6.5 months and the OS became 12.5 months. 10 months have passed since then. Come 9/16/22, could the OS go to 20+ months?”
36 months would lead us to believe we basically cured cancer at this point? Maybe this is why the data is urgent?
I don’t want to get my hopes up, but once again ohm is this actually possible? Obviously nobody can really answer that without the data but this just seems too good to be true.
“Come 9/16/2022, we should be able to learn what the more refined PFS is for these 21 patients and what the more refined Overall Survivability is for these 21 patients. The study started 4/22/2019. By 7/19/21, the PFS was 8 months and the OS was 36 months. Since then, 13 months have passed. All in All, the patients were not very healthy. It was a combination of Compassionate Use, brain metastasis and patients had failed 2 other treatment protocols. Patients were treated differently, and may only have received up to 4 doses of leronlimab + carboplatin total while some other received much more, however, leronlimab may have been dosed even after PFS endpoint was reached and after the cancer had returned which may have extended OS. Hopefully, all of this is documented in the results of the trial. From the 7/19/21 PR above, we currently had a PFS of 8 months and an OS of 36 months. Since November 2021, the PFS was recalculated to be 6.5 months and the OS became 12.5 months. 10 months have passed since then. Come 9/16/22, could the OS go to 20+ months?”
(4)
(0)